Biohaven reports Q4 net loss $144.8M, cash $385.5M; key pipeline data milestones in 2024

Biohaven Ltd.

2023-FY EPS reported -$5.73

Q4 2023 net loss $144.8M ($1.81/sh); non-GAAP adj net loss $128.9M ($1.61/sh).
Cash, equivalents & securities $385.5M as of Dec 31, 2023 (incl. $3.7M restricted).
Public offering closed Oct 2023: 11.76M shares at $22, net proceeds ~$242.4M.
BHV-1300 Phase 1 IgG lowering data expected late Q1/early Q2 2024.
Troriluzole Phase 3 OCD interim analysis topline results expected Q2 2024; taldefgrobep SMA data H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biohaven Ltd. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.

View on SEC.gov

Browse all earnings releases →

Biohaven Ltd. filing history →

Source: SEC EDGAR

accession 0001935979-24-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.